Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

Blood (2024) 144 (22): 2295–2307.

https://doi.org/10.1182/blood.2024024789

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of Neurological and Psychiatric Comorbidities on Toxicity and Outcomes of Patients with DLBCL Who Receive Axicabtagene Ciloleucel

Rebecca Albuquerque, Anna Shamis, Athanasios Tsalatsanis, Ambuj Kumar, Zain Ahmad, Hasiq Ovais, Aleksandr Lazaryan, Farhad Khimani, Rawan Faramand, Ciara Louise Freeman, Bijal D Shah, Sameh Gaballa, Julio C. Chavez, Fabiana Perna, Jose L. Ochoa-Bayona, Frederick L. Locke, Michael D. Jain, Taiga Nishihori, Abu-Sayeef Mirza

Blood (2024) 144 (Supplement 1): 7734.

https://doi.org/10.1182/blood-2024-208905

Published: 2024

Journal Articles

Impact of Autoimmune Disease on Toxicity and Outcomes after Axicabtagene Ciloleucel in Patients with Diffuse Large B Cell Lymphoma

Anna Shamis, Rebecca Albuquerque, Athanasios Tsalatsanis, Ambuj Kumar, Zain Ahmad, Hasiq Ovais, Aleksandr Lazaryan, Farhad Khimani, Rawan Faramand, Ciara Louise Freeman, Bijal D Shah, Sameh Gaballa, Julio C. Chavez, Fabiana Perna, Jose L. Ochoa-Bayona, Frederick Locke, Michael D. Jain, Taiga Nishihori, Abu-Sayeef Mirza

Blood (2024) 144 (Supplement 1): 7733.

https://doi.org/10.1182/blood-2024-208743

Published: 2024

Journal Articles

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 1048.

https://doi.org/10.1182/blood-2024-210830

Published: 2024

Journal Articles

Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy

Jamila Mammadova, Yanina Pasikhova, Jongphil Kim, Junmin Whiting, Farhad Khimani, Michael D. Jain, Sayeef Mirza, Rawan Faramand, Julio C. Chavez, Bijal D Shah, Olga Klinkova, Aliyah Baluch, Jose L. Ochoa-Bayona, Fabiana Perna, Taiga Nishihori, Nelli Bejanyan, Frederick Locke, Aleksandr Lazaryan

Blood (2024) 144 (Supplement 1): 2103.

https://doi.org/10.1182/blood-2024-201878

Published: 2024

Journal Articles

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Blood (2024) 144 (Supplement 1): 2071.

https://doi.org/10.1182/blood-2024-208021

Published: 2024

Journal Articles

Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide

Blood (2024) 144 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2024-209164

Published: 2024

Journal Articles

Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia

Abida Babu, Kathryn Bower, Madiha Siraj, Biwei Cao, Jongphil Kim, Hany Elmariah, Rawan Faramand, Sayeef Mirza, Lia Perez, Asmita Mishra, Farhad Khimani, Jose L. Ochoa-Bayona, Michael Nieder, Taiga Nishihori, Joseph A. Pidala, Nelli Bejanyan

Blood (2024) 144 (Supplement 1): 4881.

https://doi.org/10.1182/blood-2024-202709

Published: 2024

Journal Articles

Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation

Blood (2024) 144 (Supplement 1): 4826.

https://doi.org/10.1182/blood-2024-202363

Published: 2024

Journal Articles

Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis

Blood (2024) 144 (Supplement 1): 4871.

https://doi.org/10.1182/blood-2024-208229

Published: 2024

Journal Articles

A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1776.

https://doi.org/10.1182/blood-2023-185117

Published: 2023

Journal Articles

Clinical Outcomes of Adults Undergoing Allogeneic Stem Cell Transplant for Secondary Acute Lymphoblastic Leukemia

Vivian Irizarry Gatell, Denise Kalos, Joseph A. Pidala, Hany Elmariah, Farhad Khimani, Asmita Mishra, Taiga Nishihori, Michael D. Jain, Michael Neider, Lia Perez, Sayeef Mirza, Bijal D. Shah, Leidy Lismeris Isenalumhe, Nelli Bejanyan, Aleksandr Lazaryan, Rawan Faramand

Blood (2023) 142 (Supplement 1): 2830.

https://doi.org/10.1182/blood-2023-180321

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide Equalizes Clinical Outcomes of Allogeneic Hematopoietic Cell Transplantation across Racial and Ethnic Populations

Teresa Caprice, Wenyi Fan, Jongphil Kim, Rawan Faramand, Asmita Mishra, Lia Perez, Farhad Khimani, Aleksandr Lazaryan, Jose L. Ochoa-Bayona, Hien Liu, Michael D. Jain, Michael Nieder, Claudio Anasetti, Taiga Nishihori, Joseph A. Pidala, Nelli Bejanyan, Hany Elmariah

Blood (2023) 142 (Supplement 1): 390.

https://doi.org/10.1182/blood-2023-186738

Published: 2023

Journal Articles

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Hany Elmariah, Jongphil Kim, Asmita Mishra, Rawan Faramand, Lia Perez, Aleksandr Lazaryan, Farhad Khimani, Hien Liu, Jose L. Ochoa-Bayona, Michael Nieder, Nicholas Figura, Timothy J Robinson, Taiga Nishihori, Claudio Anasetti, Joseph A. Pidala, Nelli Bejanyan

Blood (2023) 142 (Supplement 1): 4900.

https://doi.org/10.1182/blood-2023-187473

Published: 2023

Journal Articles

Cladribine and Cyclophosphamide Lymphodepletion Prior to Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4884.

https://doi.org/10.1182/blood-2023-187078

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies

Jeffery J. Auletta, Monzr M. Al Malki, Todd DeFor, Brian C. Shaffer, Mahasweta Gooptu, Javier Bolanos-Meade, Ramzi Abboud, Adrienne D. Briggs, Farhad Khimani, Dipenkumar Modi, Richard Newcomb, Elizabeth J. Shpall, Caitrin Bupp, Stephen R. Spellman, Heather E. Stefanski, Antonio M. Jimenez Jimenez, Steven M. Devine

Blood (2023) 142 (Supplement 1): 780.

https://doi.org/10.1182/blood-2023-172722

Published: 2023

Journal Articles

Ibrutinib Added to Standard Conditioning and As Consolidation Therapy Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Primary Analysis of the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201

Charalambos Andreadis, Olivia Bobek, Eric D. Hsi, Timothy S. Fenske, Susan M. Geyer, Patrick J. Stiff, Brian T. Hill, Mitchell Horwitz, Farhad Khimani, Richard F. Little, Shira N. Dinner, Jonathan W. Friedberg, Brad S. Kahl, Miguel-Angel Perales, Steven M. Devine, John P. Leonard, Nancy L. Bartlett

Blood (2023) 142 (Supplement 1): 437.

https://doi.org/10.1182/blood-2023-173742

Published: 2023

Journal Articles

JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

Joseph Pidala, Shernan G. Holtan, Kelly Walton, Jongphil Kim, Hany Elmariah, Asmita Mishra, Nelli Bejanyan, Taiga Nishihori, Farhad Khimani, Lia Perez, Rawan Faramand, Marco Davila, Claudio Anasetti, Daniel Weisdorf, Bruce R Blazar, Jeffrey S Miller, Veronika Bachanova, Najla H El Jurdi, Brian C Betts

Blood (2023) 142 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2023-173376

Published: 2023

Journal Articles

Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia

Blood (2023) 142 (Supplement 1): 3512.

https://doi.org/10.1182/blood-2023-185097

Published: 2023

Journal Articles

Impact of Sarcopenia and Subsequent Muscle Loss on Post-CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2023-187294

Published: 2023

NARROW

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

Impact of Neurological and Psychiatric Comorbidities on Toxicity and Outcomes of Patients with DLBCL Who Receive Axicabtagene Ciloleucel

Impact of Autoimmune Disease on Toxicity and Outcomes after Axicabtagene Ciloleucel in Patients with Diffuse Large B Cell Lymphoma

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide

Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia

Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation

Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis

A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Clinical Outcomes of Adults Undergoing Allogeneic Stem Cell Transplant for Secondary Acute Lymphoblastic Leukemia

Post-Transplant Cyclophosphamide Equalizes Clinical Outcomes of Allogeneic Hematopoietic Cell Transplantation across Racial and Ethnic Populations

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Cladribine and Cyclophosphamide Lymphodepletion Prior to Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma

Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies

JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia

Impact of Sarcopenia and Subsequent Muscle Loss on Post-CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only